Sweden· SE-20121223000012
Lemtrada 12 mg Koncentrat till infusionsvätska, lösning
A medicinal product containing alemtuzumab, registered in Sweden by Sanofi Belgium.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Alemtuzumab
- Manufacturer
- Sanofi Belgium
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20121223000012
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alemtuzumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLemtrada 12 mgSanofi Belgium
- CzechiaLEMTRADASanofi Belgium, Belgie
- FinlandLemtradaSanofi Belgium
- IrelandLEMTRADA 12 mg concentrate for solution for infusionSanofi Belgium
- IcelandLemtradaSanofi Belgium
- United KingdomLemtrada 12mg/1.2ml concentrate for solution for infusion vialsSanofi
- United StatesCampathGenzyme Corporation
- CanadaLEMTRADASANOFI-AVENTIS CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lemtrada
- Liechtenstein · Lemtrada
- Norway · Lemtrada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/45879710-f1da-4e0f-bb56-fa94f2b4f2c2 GET /v1/drugs/45879710-f1da-4e0f-bb56-fa94f2b4f2c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"Dispensbeslut",
"EPAR",
"EMA"
],
"se_npl_id": "20121223000012",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20121223000012",
"product_doc_link": "https://docetp.mpa.se/LMF/Lemtrada%2C%20sammanfattning%20av%20beslut%2C%20giltigt%20fr.o.m.%202026-02-04%20t.o.m.%202030-01-01%20%28f%C3%B6rp.%20med%20engelsk%20m%C3%A4rkning%20och%20engelsk%20bipacksedel%29_09001bee84ef68d0.pdf"
}See everything about alemtuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.